vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and Tyler Technologies (TYL). Click either name above to swap in a different company.

Tyler Technologies is the larger business by last-quarter revenue ($613.5M vs $321.1M, roughly 1.9× MADRIGAL PHARMACEUTICALS, INC.). Tyler Technologies runs the higher net margin — 13.2% vs -18.2%, a 31.5% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 8.6%). Tyler Technologies produced more free cash flow last quarter ($2.0M vs $-133.8M).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Tyler Technologies, Inc. is an American technology company based in Plano, Texas, that provides proprietary software to the U.S. public sector. Tyler Technologies has offices in 17 states and one in Toronto, Ontario, Canada.

MDGL vs TYL — Head-to-Head

Bigger by revenue
TYL
TYL
1.9× larger
TYL
$613.5M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+202.2% gap
MDGL
210.8%
8.6%
TYL
Higher net margin
TYL
TYL
31.5% more per $
TYL
13.2%
-18.2%
MDGL
More free cash flow
TYL
TYL
$135.9M more FCF
TYL
$2.0M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MDGL
MDGL
TYL
TYL
Revenue
$321.1M
$613.5M
Net Profit
$-58.6M
$81.2M
Gross Margin
48.3%
Operating Margin
-18.6%
16.3%
Net Margin
-18.2%
13.2%
Revenue YoY
210.8%
8.6%
Net Profit YoY
1.4%
EPS (diluted)
$-2.55
$1.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
TYL
TYL
Q1 26
$613.5M
Q4 25
$321.1M
$575.2M
Q3 25
$287.3M
$595.9M
Q2 25
$212.8M
$596.1M
Q1 25
$137.3M
$565.2M
Q4 24
$103.3M
$541.1M
Q3 24
$62.2M
$543.3M
Q2 24
$541.0M
Net Profit
MDGL
MDGL
TYL
TYL
Q1 26
$81.2M
Q4 25
$-58.6M
$65.5M
Q3 25
$-114.2M
$84.4M
Q2 25
$-42.3M
$84.6M
Q1 25
$-73.2M
$81.1M
Q4 24
$-59.4M
$65.2M
Q3 24
$-107.0M
$75.9M
Q2 24
$67.7M
Gross Margin
MDGL
MDGL
TYL
TYL
Q1 26
48.3%
Q4 25
45.5%
Q3 25
47.2%
Q2 25
45.8%
Q1 25
96.7%
47.3%
Q4 24
43.8%
Q3 24
43.7%
Q2 24
44.0%
Operating Margin
MDGL
MDGL
TYL
TYL
Q1 26
16.3%
Q4 25
-18.6%
13.0%
Q3 25
-39.7%
16.4%
Q2 25
-22.2%
16.0%
Q1 25
-57.8%
15.8%
Q4 24
-64.8%
13.2%
Q3 24
-187.1%
15.2%
Q2 24
14.4%
Net Margin
MDGL
MDGL
TYL
TYL
Q1 26
13.2%
Q4 25
-18.2%
11.4%
Q3 25
-39.8%
14.2%
Q2 25
-19.9%
14.2%
Q1 25
-53.4%
14.3%
Q4 24
-57.5%
12.1%
Q3 24
-172.0%
14.0%
Q2 24
12.5%
EPS (diluted)
MDGL
MDGL
TYL
TYL
Q1 26
$1.88
Q4 25
$-2.55
$1.50
Q3 25
$-5.08
$1.93
Q2 25
$-1.90
$1.93
Q1 25
$-3.32
$1.84
Q4 24
$-2.50
$1.48
Q3 24
$-4.92
$1.74
Q2 24
$1.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
TYL
TYL
Cash + ST InvestmentsLiquidity on hand
$198.7M
$346.4M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$602.7M
$3.6B
Total Assets
$1.3B
$4.8B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
TYL
TYL
Q1 26
$346.4M
Q4 25
$198.7M
$1.1B
Q3 25
$295.7M
$950.8M
Q2 25
$186.2M
$892.3M
Q1 25
$183.6M
$807.4M
Q4 24
$100.0M
$768.0M
Q3 24
$232.7M
$544.3M
Q2 24
$258.0M
Total Debt
MDGL
MDGL
TYL
TYL
Q1 26
Q4 25
$339.9M
$599.7M
Q3 25
$339.8M
$599.2M
Q2 25
$118.4M
$598.8M
Q1 25
$118.0M
$598.4M
Q4 24
$117.6M
$597.9M
Q3 24
$117.1M
$597.5M
Q2 24
$597.1M
Stockholders' Equity
MDGL
MDGL
TYL
TYL
Q1 26
$3.6B
Q4 25
$602.7M
$3.7B
Q3 25
$625.7M
$3.6B
Q2 25
$696.0M
$3.6B
Q1 25
$710.6M
$3.5B
Q4 24
$754.4M
$3.4B
Q3 24
$777.2M
$3.3B
Q2 24
$3.1B
Total Assets
MDGL
MDGL
TYL
TYL
Q1 26
$4.8B
Q4 25
$1.3B
$5.6B
Q3 25
$1.4B
$5.5B
Q2 25
$1.0B
$5.4B
Q1 25
$996.6M
$5.2B
Q4 24
$1.0B
$5.2B
Q3 24
$1.1B
$5.0B
Q2 24
$4.8B
Debt / Equity
MDGL
MDGL
TYL
TYL
Q1 26
Q4 25
0.56×
0.16×
Q3 25
0.54×
0.17×
Q2 25
0.17×
0.16×
Q1 25
0.17×
0.17×
Q4 24
0.16×
0.18×
Q3 24
0.15×
0.18×
Q2 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
TYL
TYL
Operating Cash FlowLast quarter
$-133.5M
$107.3M
Free Cash FlowOCF − Capex
$-133.8M
$2.0M
FCF MarginFCF / Revenue
-41.7%
0.3%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.32×
TTM Free Cash FlowTrailing 4 quarters
$585.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
TYL
TYL
Q1 26
$107.3M
Q4 25
$-133.5M
$243.9M
Q3 25
$79.8M
$255.2M
Q2 25
$-47.1M
$98.3M
Q1 25
$-88.9M
$56.2M
Q4 24
$-104.5M
$224.8M
Q3 24
$-67.0M
$263.7M
Q2 24
$64.3M
Free Cash Flow
MDGL
MDGL
TYL
TYL
Q1 26
$2.0M
Q4 25
$-133.8M
$239.6M
Q3 25
$79.0M
$251.3M
Q2 25
$92.8M
Q1 25
$53.8M
Q4 24
$-104.7M
$221.0M
Q3 24
$-67.8M
$260.8M
Q2 24
$57.7M
FCF Margin
MDGL
MDGL
TYL
TYL
Q1 26
0.3%
Q4 25
-41.7%
41.7%
Q3 25
27.5%
42.2%
Q2 25
15.6%
Q1 25
9.5%
Q4 24
-101.3%
40.8%
Q3 24
-109.0%
48.0%
Q2 24
10.7%
Capex Intensity
MDGL
MDGL
TYL
TYL
Q1 26
Q4 25
0.1%
0.8%
Q3 25
0.3%
0.7%
Q2 25
0.0%
0.9%
Q1 25
0.0%
0.4%
Q4 24
0.2%
0.7%
Q3 24
1.3%
0.5%
Q2 24
1.2%
Cash Conversion
MDGL
MDGL
TYL
TYL
Q1 26
1.32×
Q4 25
3.72×
Q3 25
3.02×
Q2 25
1.16×
Q1 25
0.69×
Q4 24
3.45×
Q3 24
3.47×
Q2 24
0.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

TYL
TYL

Subscriptions$429.7M70%
Maintenance$108.9M18%
Other$74.9M12%

Related Comparisons